Featured « AGORACOM Small-cap Investor Relations Blog

Archive for the ‘Featured’ Category

Datametrex $DM.ca Secures COVID-19 Antigen Detection Kits

Posted by AGORACOM-JC at 9:10 AM on Wednesday, August 12th, 2020

Announced that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits
These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes
Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection

TORONTO, Aug. 12, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits. These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes.

The Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection. It is an in-vitro diagnostic medicaldevice to detect the SARS-CoV-2 antigen from a person’s oropharyngeal and nasopharyngeal secretions if the specimen contains antigens to SARS-CoV-2, a colored line appears in the T line area.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy,” said Marshall Gunter, CEO of Datametrex. “These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

PCL states that the clinical sensitivity (confirmed the actual positive of the approved person) is 100% and the clinical specificity (confirmed the actual negative of the negative person) is 97.78%. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

The following certifications have been awarded to these PCL Antigen Test Kits: CE Certificate, Korea FDA, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East- Qatar and UAE, India, Russia, 3 countries in Latin America- Guatemala, Ecuador, and Colombia.

The PCL Antigen Detection kit has the CE Certificate meaning that the manufacturer and products have met EU declaration of standards for health, safety, and environmental protection, allowing this product to be sold within the 22 countries in the European Economic Area.

Worldwide, currently there have been over 19.7M people who have been tested positive for COVID-19 but the actual case count is believed to be higher, as a significant number of asymptomatic people may not have been tested. Even more worrying is that most families have had to wait more than 72 hours for their test results to come back from both public and private labs increasing the possibility of spreading the virus.

Rapid Diagnosis Kit is easy when there are no symptoms even after COVID-19 infection, or when ‘positive’ and ‘negative’ are not evident in tests such as RT-PCR. When an infection occurs, an antigen against COVID-19 is formed in the body after some time, so it is a post-test that is essential as a preventive measure.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Health Canada must approve these COVID-19 test kits before they can be used in Canada. The Company plans to sell these kits in all countries where the kits have been approved for sale.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

About Datametrex

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Forward-Looking Statements

Tags: AI, Antigen Rapid Diagnosis, bot, covid19, CSE, datametrex, investments, PCL, small cap
Posted in All Recent Posts, Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Secures COVID-19 Antigen Detection Kits

Avicanna’s $AVCN.ca RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical #Cannabis by #Shoppers Inc.™ $TRUL.ca $ACB

Posted by AGORACOM-JC at 8:08 AM on Wednesday, August 12th, 2020

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners on the Medical Cannabis by Shoppers™ platform.

This product line includes advanced formulations under the “Cannabis 2.0” regulations that have undergone years of research and development and been manufactured under GMP standards at MediPharm Labs Inc.

The RHO Phyto products are also now available to clinicians and patients at the University Health Network through the Medical Cannabis Real World Evidence study in partnership with Medical Cannabis by Shoppers.

TORONTO, Aug. 12, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its advanced RHO Phyto™ Micro Drop oils are now officially available nationwide in Canada on the Medical Cannabis by Shoppers™ (“Shoppers“) platform as well as through the Medical Cannabis Real-World Evidence study (“MC-RWE study“) at the University Health Network (“UHN“) as announced by the Company on July 15, 2020.

Following years of research and development in collaboration with world class academic and clinical organizations, Avicanna is proud to be launching RHO Phyto, a full formulary of advanced medical cannabis products, for patients and the medical community in Canada. Following the Micro Drop oils, Avicanna expects to launch two advanced sublingual spray formulations in the upcoming weeks. The RHO Phyto product line includes oil drops, sublingual sprays, capsules and topicals with varying ratios of CBD and THC. The RHO Phyto products are designed to address a range of medical conditions that may require various rates of relief. For example, the “Rapid Act” sublingual sprays provide a faster onset of effects than the “Simple Dose” capsules and “Micro Drop” oils. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured under Good Manufacturing Practices (“GMP“) in partnership with MediPharm Labs Inc. and GMP-level analytical testing is performed by Sigma Analytical Services Inc. All RHO Phyto products will be tracked using blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.

Aras Azadian, CEO of Avicanna commented, “We believe that our RHO Phyto formulary is designed to address numerous gaps in the current medical cannabis framework with respect to patient needs and provide an opportunity to attract new prescribers and patients to medical cannabis solutions. The introduction of a strictly medical line of products, backed by extensive research, pre-clinical data, GMP manufacturing and offered by Shoppers, has the opportunity to set a new standard of care and establish RHO Phyto as the leading medical product line in the medical cannabis market.”

With the patient in mind, RHO Phyto Micro Drop oils are formulated with enhanced absorption, prolonged stability, and consistency. The blood orange flavoured Micro Drop oil 1.6 CBD – 0.06 THC and Micro Drop oil 0.6 CBD – 0.16 THC are available in a 25:1 and 4:1 CBD to THC ratio, respectively. The product name includes the amount in milligrams (mg) of CBD and THC that is delivered per dose. Detailed guidelines about dosing and titration for Health Care Practitioners (“HCPs“) and patients is available on the RHO Phyto website at www.rhophyto.com, as well as on the Avicanna Academy website at https://www.avicanna.com/the-avicanna-academy/, along with additional product information, product guidelines for patients, and frequently asked questions.

As a part of Avicanna’s commercialization strategy, the Company will be providing education and training for HCPs, patients, and medical institutions about medical cannabis and the RHO Phyto product line. Educational materials can be found on the Avicanna Academy website at https://www.avicanna.com/the-avicanna-academy/, including a recording of Avicanna’s 3rd annual symposium that was hosted virtually in partnership with Shoppers on July 21st and was live-streamed by over 1,000 participants.

The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as MyCannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care and education to their patients on the considerations and benefits that medical cannabis has to offer. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

Pura H&W: an advanced and clinically tested line of CBD consumer dermacosmetic products; and,
RHO Phyto: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its dermacosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

About My Cannabis Clinic

My Cannabis Clinic, a wholly-owned subsidiary of Avicanna, is an online health care platform that specializes in providing residents of Canada with access to cannabis and cannabinoid products for medical use. My Cannabis Clinic is devoted to providing its patients with support and education needed while using medical cannabis. My Cannabis Clinic believes in providing quality care and education to our patients about the medicinal benefits that cannabis has to offer.

Stay Connected

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to launch the RHO Phyto sublingual spray at Shoppers, the ability of the RHO Phyto products to address a range of medical conditions that may require various rates of relief, the ability of the RHO Phyto formulary to address numerous gaps in the current medical cannabis framework as well as patient needs, the ability of the Company to conduct clinical trials using various RHO Phyto products in collaboration with various leading Canadian medical institutions and the likelihood of such clinical trials evaluating the safety, tolerability and efficacy of the RHO Phyto products for treating a range conditions such as chronic pain, inflammatory bowel disorder, and their associated co-morbidities. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

Tags: cannabinoids, CSE, Marijuana, Medical Cannabis by Shoppers, Rho Phyto
Posted in Avicanna Inc., Featured | Comments Off on Avicanna’s $AVCN.ca RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical #Cannabis by #Shoppers Inc.™ $TRUL.ca $ACB

Innocan $INNO.ca Engages Endless Sky to Manufacture and Distribute Innocan’s CBD Cosmetic Products in Canada $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:09 PM on Tuesday, August 11th, 2020

Entered into a manufacturing and distribution agreement with Endless Sky Incorporated, a Canadian large scale Cannabis extractor based in Calgary, Alberta
Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan.
ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream.

Herzliya, Israel and Calgary, Alberta – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel”) has entered into a manufacturing and distribution agreement (the “Agreement”) with Endless Sky Incorporated (“ESI”), a Canadian large scale Cannabis extractor based in Calgary, Alberta.

Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream. The Agreement conditional upon ESI receiving Health Canada’s approval no later than December 31, 2020. According to the agreement, ESI shall pay Innocan Israel a cash license fee per Product as well as royalties based on net sales of the Products by ESI.

The Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months each based on ESI achieving minimum sales targets for the previous 12 months period.

ESI is responsible for meeting all Canadian regulations and registrations.

“Endless Sky is thrilled to exclusively manufacture and distribute Innocan’s SHIR Beauty & Science skin care line as well their Relief & Go topical products in Canada, with the future potential to access additional countries where cannabis regulations permit, and terms agreed by the parties. We believe that Innocan’s patent-pending, CBD-integrated products will be some of the highest quality CBD products to enter the market to date. Israel is well known as the global leader in CBD research and Innocan is leveraging that knowledge with a team of proven experts in the cosmetics, healthcare, sports medicine, and wellness markets. Innocan’s diligent commitment to research and development and its visionary thinking has positioned both companies to be market leaders in the CBD consumer packaged goods products space. The pharmaceutical expertise of Innocan together with Endless Sky’s large extraction capacity and manufacturing capabilities will combine to bring top of the line products to market at scale and price points that will allow for wide market access. This Agreement also positions both companies for CBD deregulation, allowing Endless Sky and Innocan’s CBD products to be further scaled through national retailers at such time. We are very excited to bring these products into the Canadian market in the very near future,” says CEO of Endless Sky, Travis George.

Iris Bincovich, Innocan’s Founder and CEO, commented: “We are thrilled to have found the right party to distribute and manufacture our CBD line of products in Canada. Distributing our CBD line of products is a significant milestone for us, given the importance of Canada to the world of CBD. Collaboration with Endless Sky, one of Canada’s largest extracting companies, will allow us to enter Innocan’s revolutionary wellness brands into the Canadian market”.

About Endless Sky Incorporated:

Endless Sky Incorporated is a Canadian large scale cannabis C02 extractor focusing on Cannabinoids. Endless Sky has a Health Canada standard processing licence which allows production of consumer packaged goods with Cannabinoids as an additive.

With top of market throughput, hemp genetics breeding program, strict QA/QC standards, and EU GMP design, Endless Sky is poised to be a global leader in low cost premium active pharmaceutical ingredients for the health, wellness and beauty markets.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: CBD, CBD Derma Cosmetics, CBD stocks, CSE, Innocan, Relief & Go Pain Relief Spray, SHIR, SHIR Skincare Products, stocks, tsx
Posted in Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Engages Endless Sky to Manufacture and Distribute Innocan’s CBD Cosmetic Products in Canada $GWPH $CRDL.ca $PCLO.ca

Esports Entertainment Group $GMBL Signs LOI to Acquire Assets of FLIP Sports $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 8:37 AM on Tuesday, August 11th, 2020

Signed a Letter of Intent to acquire certain assets of FLIP Sports Limited, including staff and all intellectual property.
FLIP Sports is a dynamic and entrepreneurial mobile games studio innovating how fans enjoy and engage with live sports.
Through its proprietary in-play, peer-to-peer technology, FLIP provides a unique multi-platform second-screen experience within an entertaining, social, and competitive gaming environment for fun-seeking sports and wagering enthusiasts who enjoy watching live sports and events.

BIRKIRKARA, Malta, Aug. 11, 2020 — Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) (or the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, signed a Letter of Intent (“LOI”) to acquire certain assets of FLIP Sports Limited (“FLIP”), including staff and all intellectual property.

“The FLIP team are leaders in building iGaming platforms that take the player experience to new heights,” stated John Brackens, CIO/CTO of Esports Entertainment Group. “Their expertise will strengthen our efforts in esports and help us further create a best-in-class immersive experience for esports fans.”

FLIP Sports is a dynamic and entrepreneurial mobile games studio innovating how fans enjoy and engage with live sports. Through its proprietary in-play, peer-to-peer technology, FLIP provides a unique multi-platform second-screen experience within an entertaining, social, and competitive gaming environment for fun-seeking sports and wagering enthusiasts who enjoy watching live sports and events.

“FLIP has brought together a talented team with proven industry experience that we believe will provide immense value to Esports Entertainment Group as we enter a period of tremendous opportunity and rapid growth,” commented Grant Johnson, CEO of Esports Entertainment Group. “As the first US-based iGaming company to list on NASDAQ, we are in a great position to capitalize on the fragmented esports market and will continue to pursue acquisition opportunities. FLIP is set to be the latest example of the success of our roll-up strategy.”

ABOUT ESPORTS ENTERTAINMENT GROUP

Esports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in Curacao, Kingdom of the Netherlands. The Company maintains offices in Malta. For more information visit www.esportsentertainmentgroup.com

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
[email protected]

Media & Investor Relations Inquiries
AGORACOM
[email protected]
http://agoracom.com/ir/eSportsEntertainmentGroup

Tags: Activision Blizzard, Apple, Draftkings Inc, EA sports, eGambling, egaming, esports, nasdaq
Posted in Esports Entertainment Group, Esports Entertainment Group Inc., eSports Investing, Featured | Comments Off on Esports Entertainment Group $GMBL Signs LOI to Acquire Assets of FLIP Sports $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Avicanna $AVCN.ca and Red White & Bloom Enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived #CBD-Based Topical Products in the United States $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 8:06 AM on Tuesday, August 11th, 2020

Entered into a distribution agreement for the exclusive distribution of Avicanna’s advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by RWB in the US and certain other markets.
The partnership allows for both companies to stake a claim in the expanding $532 billion beauty industry with the most advanced and only clinically backed CBD skin care line

TORONTO, Aug. 11, 2020 – Avicanna Inc. (“Avicanna”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, and Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) (“RWB” or “Red White & Bloom”) are pleased to announce that they have entered into a distribution agreement for the exclusive distribution of Avicanna’s advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by RWB in the US and certain other markets.

The $532 billion beauty industry continues growing rapidly and new trends such as the introduction of CBD cosmetics is anticipated to establish a strong market presence in markets that permit retail sales such as the United States. The Pura H&W branded products utilize hemp-derived CBD, the non-psychoactive and non-controlled cannabinoid, which allows for cosmetic designation and retail sales.

The launch of this innovative and premium hemp-derived CBD product line will leverage from the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform, third party e-commerce channels, and “big box” retailers in addition to the existing commercial infrastructure of RWB in the United States.

Brad Rogers, chairman and chief executive officer of RWB, stated: “Throughout my career, I have seen tremendous success licensing brands, strategically leveraging them for the demographics that recognize the best in class quality & efficacy, and then listing them in big box and specialty retailers. This agreement paves a path that will allow RWB and Avicanna to grow together well into the future beyond our news today.”

Under the agreement, which has an initial five-year term, RWB will exclusively distribute the Pura H&W™ brand and certain other white label brands at RWB’s direction. Having been developed by researchers and collaborators from world class medical and academic institutions, the Pura H&W™ line of products has been developed through a scientific and evidence-based approach. This approach in product development has allowed Avicanna to synergistically combine natural ingredients with hemp-derived CBD in advanced and proprietary formulations that have completed 3 cosmetic human clinical studies. Product development is always commenced with the consumer in mind and specific needs are addressed through analysis in observational as well as interventional clinical studies. Avicanna’s hemp-derived CBD infused cosmetics and topicals equip RWB with the opportunity to set the standards with advanced research and development for hemp-derived CBD cosmetics and GMP manufacturing.

The 3 cosmetic clinical studies were completed on Avicanna’s formulations targeted at cosmetic factors associated with aging, acne-prone skin, and eczema-prone skin. The successfully completed studies involved 156 patients that were tested for both safety and certain derma-cosmetic endpoints, including hydration and excess oil production. The results of all three studies achieved positive results in the endpoints with no adverse effects, making products part of one of the only cannabinoid consumer product lines with human safety and efficacy data.

Aras Azadian, CEO of Avicanna, commented: “After years of R&D and clinical development of what we believe is the most advanced line of CBD skin care products, we are thrilled to have partnered up with the team at RWB, who provide an ideal partner for Avicanna and the Pura H&W line of products. We believe their access and expertise in the US market through commercial and retail channels will allow the Pura H&W branded products to reach their potential as the leading skin care brand.”

Terms of the agreement

RWB will pay Avicanna an upfront licensing fee in the amount of two hundred fifty thousand Canadian dollars (CAD$250,000) in cash, along with minimum purchase requirements for the rights to be the exclusive distributor of Avicanna’s Pura H&W branded cosmetic products in the US. Under the agreement, RWB also has the right to purchase Avicanna’s cosmetic products for distribution into the US and certain other territories under brands of RWB’s choosing. The initial product offerings under the agreement will include body and face lotions, cosmetic creams, gels and serums, as well as soaps and bath bombs.

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Red White & Bloom Brands Inc.

The Company is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominately focusing its investments on the major US markets, including Michigan, Illinois, Massachusetts, California, and Florida with respect to cannabis, and the US and internationally for hemp-based CBD products.

For more information about Red White & Bloom Brands Inc., please contact:

Tyler Troup, Managing Director

Circadian Group IR

[email protected]

Visit us on the web: www.RedWhiteBloom.com

Follow us on social media:

Twitter: @rwbbrands

Facebook: @redwhitebloombrands

Instagram: @redwhitebloombrands

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of Avicanna or RWB to perform under the agreement, the manufacturing of the products, the shipping and delivery of the products to customers in the United States and worldwide, and the appropriate education and marketing efforts. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

Tags: cannabinoids, CSE, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, stocks
Posted in Avicanna Inc., Featured | Comments Off on Avicanna $AVCN.ca and Red White & Bloom Enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived #CBD-Based Topical Products in the United States $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Else Nutrition $BABY.ca Announces North American Launch of World’s Only Real Alternative to Dairy-Based Baby Nutrition $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:22 AM on Tuesday, August 11th, 2020

http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Baby Nutrition Paradigm shift: After 120 years, Else introduces a completely novel protein source for baby nutrition (over one year old) with a breakthrough, clean and sustainable production process.
Globally patented, and founded by infant nutrition industry veterans, Else Nutrition is the first dairy and soy- free, clean label, plant-based complete nutrition for babies (1 year and over).
A Revolution in the way babies are fed, Else Nutrition offers parents a great- tasting, dairy-free, soy-free and GMO-free alternative.
Else Plant-Based Complete Nutrition is now available for purchase at elsenutrition.com, U.S. shipping nationwide and to Canada.

VANCOUVER, BC / August 11, 2020 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY) (OTCQX:BABYF) (FSE:0YL) (“Else” or the “Company“), today announces the online product launch of its Else Plant-Based Complete Toddler Nutrition, the first fully certified USDA Organic, Clean Label, Plant-Based, Soy-Free nutritional drink for toddlers. Made with ingredients, vitamins and minerals that help support growth and development after a baby’s first year. Else Plant-Based Complete Nutrition is the only globally-patented, real alternative for babies beyond the first year – including those with milk intolerances/sensitivities, those looking to avoid dairy and soy, and for all families looking for a clean, plant-based option for their children

Dairy-free, soy-free, corn syrup-free, gluten-free and non-GMO, Else Nutrition is a unique globally patented combination of whole-plant organic ingredients – almonds buckwheat and tapioca. This combination meets the gold standard equivalent of human milk nutritional composition values, based on WHO international standards, among others. Else Plant- Nutrition meets the strictest regulatory requirements and the highest nutrition standards, providing a full essential amino acid profile and a clean source of protein. It is manufactured in an infant grade U.S. manufacturing site and endorsed by a board of leading U.S. and international pediatricians and nutritionists.

“We are thrilled that today marks a huge leap forward in plant-based alternatives in the baby and toddler category,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “For more than 120 years, cow’s milk and soy have dominated. After seven years of R&D, we are finally able to offer something else to parents and bring a real, clean label alternative to families across North America, so that they will never have to compromise on the health and nutrition of their toddler again.”

Else Plant-Based Complete Nutrition for Toddlers is minimally processed. Else intends for all its future products to meet this standard. With more than seven years of research and development, Else’s breakthrough process creates nutrition products from whole plants without altering their chemistry or using highly-processed extracts, or harsh chemicals. Through this disruptive process, Else is able to maximize the nutritional value and minimize environmental impact.

Additionally, Else Nutrition’s innovation pipeline includes a breakthrough, plant-based, clean label infant formula for babies 0-12 months. It is anticipated to launch in approximately two years, currently on its pathway for final FDA approval.

Beyond the brand’s Advisory Board of Pediatricians and nutritionists, Else has already captured the attention of many influential mothers, such as Hilaria Baldwin. As a mother of four with the fifth on the way, Hilaria came across Else as she searched for nutrition products for her toddler Romeo. After using the product, Hilaria decided to partner with Else to support its product launch.

Else Plant-Based Complete Nutrition for Toddlers is now available at elsenutrition.com, currently priced at $36 for a single 22 oz. powder canister and $136 for a 4-pack. The product will also be offered on Amazon.com later this month and in select retail chains sometime during Q4 2020.

Disruptive, ‘Beyond Organic’ Production Process

Else products are minimally processed, using the cleanest production process in the infant nutrition industry. Else’s ‘Beyond Organic’ disruptive manufacturing process transforms whole plants to tasty toddler nutrition, without using highly-processed extracts or derivatives, harsh chemicals, or high-fructose corn syrup. Changing only the texture of the plants, and never the fundamental chemistry, allowing for more of the nutrients that nature intended to nourish the child.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

Media Contact:

Covet Consumer Business Unit
Gianna Totaro
[email protected]
P: 1-301-875-6574

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will,” “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: baby food, CSE, investing, organic, small cap, stocks, tsx
Posted in Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca Announces North American Launch of World’s Only Real Alternative to Dairy-Based Baby Nutrition $KMB $BMY $ABT $WYE

Empower $CBDT.ca #Covid19 Testing Growth Adds to Revenue Diversification with Record July 2020 Patient Visits and Record Revenue Per Patient $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:18 AM on Tuesday, August 11th, 2020

Empower July 2020 patient volume surpasses 2,300 patients with Sun Valley Health increasing revenue per patient by 29%,
Adds 426 COVID-19 patient tests in July 2020 pilot testing program

VANCOUVER, BC / AUGUST 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company continues to execute on its plan to diversify revenue sources with 2,317 patient visits in July 2020 with record revenues coming from medical cannabis certifications, naturopathic consultations, product sales, identification card production and COVID-19 testing services.

“Diversification of revenue sources utilizing the strength of our clinic, physician, technology and operational assets has been a mission of ours.” said Steven McAuley, Chairman & CEO of Empower. “To see our team, deliver record performance in such a challenging environment, validates our execution strategy, validates the daily commitment of our team members and demonstrates we are on the right path to delivering significant shareholder value.”

The Arizona Department of Health Services announced yesterday its Phased Reopening Plan for Paused Industries indicating that community spread remains: Substantial based on the status of three main criteria: 1) Cases per 100,000 individuals: Substantial, 2) Percent positivity: Substantial, and 3) Hospital visits for COVID-like illnesses in the region: Substantial.

A dashboard available at azhealth.gov/businessCOVID19 indicates whether counties meet the recommended benchmarks for reopening of gyms, movie theaters, waterparks, tubing venues, and bars.

Further information is available at:

https://www.azdhs.gov/director/public-information-office/index.php#news-release-081020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company conducts COVID-19 testing in its clinics under a four-phase national launch in the United States.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: CBD, CSE, Dosed Movie, Dosed Wellness, Hemp, tsx
Posted in Empower Clinics Inc., Featured | Comments Off on Empower $CBDT.ca #Covid19 Testing Growth Adds to Revenue Diversification with Record July 2020 Patient Visits and Record Revenue Per Patient $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

VIDEO: Vegaste Technologies $VEGA.ca Closes 1st Day Of Trading With $75,000,000 Market Cap & Revenue Run Rate Of $US 3,000,000

Posted by AGORACOM-JC at 8:02 PM on Monday, August 10th, 2020

AGORACOM prides itself on becoming the discovery platform of emerging disruptive companies …. and we’ve discovered another one today in Vegaste Technologies, an e-commerce driven platform that is delivering all things plant-based to customers across Canada right now.

Vegaste has already started with both plant-based food meals directly to homes, thanks to partnerships right across the country – but isn’t stopping there as it adds hundreds of products to the platform. More than just lip service, Vegaste is already on a $US 3,000,000 run rate and that will probably accelerate in the coming months as marketing and additional products kick in.

Vegaste Founder, Sean Dollinger, is no stranger to AGORACOM followers as he was the Co-Founder behind wildly successful Namaste Technologies before it fell on hard times experienced by the cannabis industry. In addition to bringing back his immense e-commerce capabilities, he’s also implemented some valuable lessons learned at Namaste when it comes to corporate governance and share structure.

One of those lessons was appointing Julia Frank as CEO and giving her the team necessary to focus on doing the best job possible. Julia’s experience combines both start-up and big corporation structures thanks to being part of start-up teams within both BMW and Daimler in Germany.

Vegaste is hot off the listing press, so if you ever wanted to get a jump on your fellow investor it doesn’t get much fresher than this ….. unless you’re ordering a plant based meal off their platform at www.PlantX.com

If you believe in the paradigm shifting nature of plant based foods, be sure to watch and share this great interview with Vegaste CEO Julia Frank CEO & Founder Sean Dollinger.

Tags: clean eats, CSE, Namaste Technologies, Plantx, stocks, tsx, tsx-v, vegan
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Vegaste Technologies | Comments Off on VIDEO: Vegaste Technologies $VEGA.ca Closes 1st Day Of Trading With $75,000,000 Market Cap & Revenue Run Rate Of $US 3,000,000

Kontrol’s $KNR.ca COVID-19 Technology Receives Initial Positive Lab Test Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 9:24 AM on Monday, August 10th, 2020

— Kontrol BioCloud® —

Announced that the detection mechanism of the Kontrol BioCloud® analyzer, has received initial positive lab results
Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments
The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time
This part of the ongoing testing is anticipated to be completed in the next two to three weeks

TORONTO, ON / August 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the detection mechanism of the Kontrol BioCloud® analyzer (“BioCloud“), has received initial positive lab results.

Can we measure for COVID-19 like we do for air quality?

Drawing from its extensive industry experience in air emissions and air quality monitoring, Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments.

“We are pleased to announce that our detection mechanism, previously announced on August 5th, 2020, has completed its initial proof of concept test results. We have now validated that our detection mechanism can detect COVID-19 specific components in air samples under a controlled experiment,” says Paul Ghezzi, Chief Executive Officer of Kontrol. “The controlled testing was conducted by independent consultants, Dr. David Heinrichs, PhD (Heinrichs Laboratory), and Dr. Jimmy Dikeakos, PhD (Dikeakos Laboratory) – experts in the study of Microbiology and Immunology.”

Next Stage of Testing

The initial testing was designed to validate the function of the detection mechanism. The testing was limited to a controlled environment with the detection mechanism, and not the complete operation of the BioCloud analyzer.

The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time. This part of the ongoing testing is anticipated to be completed in the next two to three weeks. It is important to note that Kontrol is not making any representations about the operation of the BioCloud analyzer at this time. Following the testing of the BioCloud analyzer in real-time the lab results will be announced, and a final report will be prepared for the National Research Council of Canada for their review.

“As we continue testing, we have also started the process of establishing procurement and supply chain solutions for the potential production of the BioCloud and we remain in discussions with the National Research Council of Canada for their continued support,” says Gary Saunders, VP of Kontrol. “Given the urgency of creating safe spaces as the economy re-opens, we are working around the clock to move our technology forward and we appreciate the efforts of our team.”

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Tags: COVID-19, CSE, energy conservation, google nest, green energy, smart building
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol’s $KNR.ca COVID-19 Technology Receives Initial Positive Lab Test Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Loop Insights $MTRX.ca Announces Reseller Partnership And First Sale With Vend, A Global POS Company Used In 25,000 Stores Across 140 Countries $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 7:09 AM on Monday, August 10th, 2020

Announced the signing of a channel reseller partnership with global cloud-based Point-of-Sale (POS) company, Vend, as well as, the first sale to a Vend client
Vend is the first POS built for iOS and is now used in over 25,000 stores across 140 countries. Vend’s fast growth and global reach creates opportunities across the world for Loop and its technology in the retail vertical.
First Implementation with Wild Bird Centers of America Inc. Franchise

VANCOUVER, BC, Aug. 10, 2020 – Loop Insights Inc. (TSXV: MTRX) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, automated marketing, and contact tracing to the brick and mortar space, is pleased to announce the signing of a channel reseller partnership with global cloud-based Point-of-Sale (POS) company, Vend, as well as, the first sale to a Vend client.

VEND UNLOCKS ACTIVE OPPORTUNITIES IN $5T GLOBAL RETAIL INDUSTRY

Vend is the first POS built for iOS and is now used in over 25,000 stores across 140 countries. Vend’s fast growth and global reach creates opportunities across the world for Loop and its technology in the retail vertical. To this end, the companies have already secured the first implementation at a Vend client, Wild Birds Centers of America Inc. – a North American aviary retail franchise with 30 stores – and subsidiary of Global Harvest Foods Ltd. Loop plans on widening the scope of opportunity Global Harvest Foods.

Furthermore, Vend is already in discussions with several other retail chains and both companies expect to announce additional implementations in the near future.

Loop Insights CEO, Rob Anson stated “This is a significant partnership for Loop given the fact both companies offer cloud-based services that provide a strong foundation for rapid scalability and growth. We are both driven to acquire multi-store clients to drive faster, larger adoption rates. As seen by our first implementation with Wild Bird Centers of America, VendHQ is already demonstrating huge value to Loop as a channel reseller. With active conversations already taking place with many of Vend’s global clients, our goals for global penetration into retail are already taking shape.”

Jake West, Director of Business Development at Vend stated “We are beyond excited to be partnering with Loop Insights to provide our retailers with robust, enterprise-level tools. With COVID 19, Vend has seen an increase in the number of mid-market and enterprise retailers that are moving to Vend to take advantage of modern, cloud-based technology. Loop Insights is a perfect complement to Vend’s platform, in that, collectively we are able to deliver enterprise & franchise reporting tools, deep product insights and even trends on consumer behavior to our retailers. Vend has long had a partner focused approach, where we partner with the best-of-breed companies like Loop to deliver our clients with an overall superior experience.

LOOP’S SOFTWARE INTEGRATION CREATES SCALABLE CHANNEL RESELLER OPPORTUNITIES

The addition of Loop’s API provides Vend clients the unique ability to connect transactional data across all physical retail locations and e-commerce platforms for single stores, multi-store franchises, and international enterprise retail customers. The companies will first integrate Loop’s powerful insights service at Wild Bird Centers of America—a franchise with 30 retail stores in Canada and the United States; Loop plans on widening the scope of opportunity to its umbrella company, Global Harvest Foods Ltd.

Without the need for hardware, Loop Cloud delivers a frictionless implementation process that allows for large-scale adoption and, ultimately, adds high margin revenue-generating power to Loop’s current Software as a Service(SaaS) revenuemodel. As a channel reseller for Loop’s technology, the companies anticipate revenue from onboarding fees and SaaS fees. Loop’s software API integration also supports seamless access to its other AI-driven services: automated personalized engagement and programmatic advertising. The addition of these services would increase the clients’ monthly SaaS fees, and add additional revenue for Loop through distribution/redemption of third-party promotions.

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&A https://agoracom.com/ir/LoopInsights/forums/discussion

About Vend: Vend is a cloud-based point-of-sale and retail management software that lets retailers run their business in-store, online, and on-the-go. Vend includes inventory management, Ecommerce integrations, customer loyalty, and reporting analytics tools. The first POS built for iOS, Vend is trusted by retailers in over 140 countries and is used in more than 25,000 stores worldwide. Vend integrates with leading tools like Bigcommerce, Quickbooks and Marsello and provides seamless integrated payment options by partnering with major banks and processors around the world. Founded in 2010, Vend has offices in Auckland, London, Toronto and Melbourne, and has raised more than $50 million from top-tier investors. For more information, please visit: https://www.vendhq.com/

About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.

Forward-Looking Statements/Information:

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LOOP Website: www.loopinsights.ai

Facebook: @LoopInsights

Twitter: @LoopInsights

LinkedIn: @LoopInsights

SOURCE LOOP Insights Inc.

Tags: AI, covid19, Covid19 tracing, CSE, internet of things, IOT, tsx, tsx-v
Posted in Featured, Loop Insights Inc. | Comments Off on Loop Insights $MTRX.ca Announces Reseller Partnership And First Sale With Vend, A Global POS Company Used In 25,000 Stores Across 140 Countries $QUIS.ca $MCLD.ca $NXO.ca

Archive for the ‘Featured’ Category

Categories